Other languages Vistagen Therapeutics, Inc.

Equities

VTGN

US92840H4002

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-20 pm EDT			5-day change	1st Jan Change
4.44 ^USD	0.00%		-1.99%	-13.62%

Apr. 25	Vistagen Announces Positive Results from Phase 2A Pilot Study of Ph15 for Improvement of Psychomotor Impairment Caused by Mental Fatigue	CI
Apr. 01	Vistagen Initiates PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder Following Positive Results of PALISADE-2	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Vistagen Announces Positive Results from Phase 2A Pilot Study of Ph15 for Improvement of Psychomotor Impairment Caused by Mental Fatigue	Apr. 25
Vistagen Initiates PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder Following Positive Results of PALISADE-2	Apr. 01
Vistagen Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Feb. 13
Vistagen to Get Patent for Neuropathic Pain Treatment Candidate in Europe	Dec. 27
Vistagen	Dec. 27
Vistagen Receives Notice from European Patent Office of Intention to Grant Patent for AV-101 to Treat Neuropathic Pain	Dec. 27
Vistagen Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	Nov. 09
Vistagen Therapeutics, Inc. Appoints Joshua Prince as the Chief Operating Officer	23-10-26
Vistagen Therapeutics, Inc. Provides Details Regarding Development Plans for Fasedienol	23-10-02
Vistagen Therapeutics Reports Positive Results From Study of Neuroactive Nasal Spray for Premenstrual Dysphoric Disorder	23-09-12
Vistagen Announces Positive Results from Exploratory Phase 2A Study of PH80 for Acute Management of the Symptoms of Premenstrual Dysphoric Disorder	23-09-12
Vistagen Therapeutics, Fuji Pharma Sign Exclusive Negotiation Deal for Japanese Market	23-09-05
Vistagen and Fuji Pharma Co., Ltd. Enter Exclusive Negotiation Agreement for Potential License to Develop and Commercialize Vistagen?s Investigational Menopausal Hot Flash Therapy, PH80 Nasal Spray, in Japan	23-09-05
Vistagen Therapeutics Hires Alnylam's Cindy Anderson to Become Finance Chief	23-08-22
Vistagen Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended June 30, 2023	23-08-10
Vistagen Therapeutics, Inc. Announces Positive Phase 3 Trial Results from Phase 3 Palisade-2 Trial of Rapid-onset Fasedienol Nasal Spray in Social Anxiety Disorder	23-08-10
Top Premarket Gainers	23-08-09
Sector Update: Health Care Stocks Advancing in Late Afternoon Trading	23-08-07
Sector Update: Health Care Stocks Rising in Afternoon Trading	23-08-07
Sector Update: Health Care	23-08-07

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Vistagen Therapeutics, Inc.

Equities

VTGN

US92840H4002

Other languages

Filters